Clinical Trial Update: Study of Anti-CD22 CAR-T Cells Treating Leukemia Children [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating anti-CD22 CAR-T cells for pediatric acute lymphoblastic leukemia has completed, including relapsed and refractory cases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CD22-CAR T Cells

Snippet

Sponsor: Beijing Boren Hospital | Conditions: Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 2 | Status: COMPLETED